JP2016513968A - Ｏ−結合ｎ−アセチルグルコサミントランスフェラーゼを標的する組成物及び方法並びに創傷治癒を促進する組成物及び方法 - Google Patents

Ｏ−結合ｎ−アセチルグルコサミントランスフェラーゼを標的する組成物及び方法並びに創傷治癒を促進する組成物及び方法 Download PDF

Info

Publication number
JP2016513968A
JP2016513968A JP2016501273A JP2016501273A JP2016513968A JP 2016513968 A JP2016513968 A JP 2016513968A JP 2016501273 A JP2016501273 A JP 2016501273A JP 2016501273 A JP2016501273 A JP 2016501273A JP 2016513968 A JP2016513968 A JP 2016513968A
Authority
JP
Japan
Prior art keywords
ogt
polynucleotide
seq
sequence
wound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016501273A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513968A5 (cg-RX-API-DMAC10.html
Inventor
ルーベンスタイン，デヴィッド
ルナガー，キャスパー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of JP2016513968A publication Critical patent/JP2016513968A/ja
Publication of JP2016513968A5 publication Critical patent/JP2016513968A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01186—Glycogenin glucosyltransferase (2.4.1.186)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01255—Protein O-GlcNAc transferase (2.4.1.255)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Power Engineering (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2016501273A 2013-03-11 2014-03-11 Ｏ−結合ｎ−アセチルグルコサミントランスフェラーゼを標的する組成物及び方法並びに創傷治癒を促進する組成物及び方法 Withdrawn JP2016513968A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775937P 2013-03-11 2013-03-11
US61/775,937 2013-03-11
PCT/US2014/023525 WO2014164805A1 (en) 2013-03-11 2014-03-11 Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing

Publications (2)

Publication Number Publication Date
JP2016513968A true JP2016513968A (ja) 2016-05-19
JP2016513968A5 JP2016513968A5 (cg-RX-API-DMAC10.html) 2017-04-13

Family

ID=51658978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016501273A Withdrawn JP2016513968A (ja) 2013-03-11 2014-03-11 Ｏ−結合ｎ−アセチルグルコサミントランスフェラーゼを標的する組成物及び方法並びに創傷治癒を促進する組成物及び方法

Country Status (13)

Country Link
US (1) US20170166897A1 (cg-RX-API-DMAC10.html)
EP (1) EP2970978A4 (cg-RX-API-DMAC10.html)
JP (1) JP2016513968A (cg-RX-API-DMAC10.html)
KR (1) KR20150126048A (cg-RX-API-DMAC10.html)
CN (1) CN105408480A (cg-RX-API-DMAC10.html)
AU (1) AU2014248966A1 (cg-RX-API-DMAC10.html)
BR (1) BR112015022701A2 (cg-RX-API-DMAC10.html)
CA (1) CA2905337A1 (cg-RX-API-DMAC10.html)
CL (1) CL2015002599A1 (cg-RX-API-DMAC10.html)
MX (1) MX2015012124A (cg-RX-API-DMAC10.html)
RU (1) RU2015138544A (cg-RX-API-DMAC10.html)
SG (1) SG11201507211YA (cg-RX-API-DMAC10.html)
WO (1) WO2014164805A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12146883B2 (en) * 2018-12-06 2024-11-19 Biocapital Holdings, Llc Glucose sensors and methods of use thereof
CN111234022B (zh) * 2019-12-16 2024-03-22 江苏省药物研究所有限公司 抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用
CN112707955B (zh) * 2020-12-21 2022-01-18 山东润德生物科技有限公司 提高N-乙酰氨基葡萄糖产量的RamAM转录因子突变体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
WO1998044123A2 (en) * 1997-03-31 1998-10-08 The Government Of The United States Of America Represented By The Secretary Of The Department Of Health And Human Services O-LINKED GlcNAc TRANSFERASE (OGT): CLONING, MOLECULAR EXPRESSION, AND METHODS OF USE
HK1042706A1 (zh) * 1998-08-03 2002-08-23 东卡罗来纳大学 低腺苷反义寡核苷酸制剂、组合物、试剂盒及处理
US7098190B1 (en) * 1999-01-27 2006-08-29 Coda Therapeutics Ltd. Formulations comprising antisense nucleotides to connexins
US20090117599A1 (en) * 2005-12-22 2009-05-07 Jun Hirabayashi METHOD OF DETECTING SUGAR CHAINS HAVING GlcNAc TRANSFERRED BY GnT-V
WO2010042228A2 (en) * 2008-10-10 2010-04-15 Cornell University Methods for predicting disease outcome in patients with colon cancer
US20120046186A1 (en) * 2010-08-20 2012-02-23 Pelham Robert J Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs
JP2012083193A (ja) * 2010-10-12 2012-04-26 Univ Of Tokyo ヒストンタンパク質のグリコシル化を検出するための方法、並びに当該方法に用いられる抗体

Also Published As

Publication number Publication date
CL2015002599A1 (es) 2016-08-26
WO2014164805A1 (en) 2014-10-09
RU2015138544A (ru) 2017-04-18
MX2015012124A (es) 2016-04-28
CN105408480A (zh) 2016-03-16
US20170166897A1 (en) 2017-06-15
BR112015022701A2 (pt) 2018-09-25
SG11201507211YA (en) 2015-10-29
CA2905337A1 (en) 2014-10-09
EP2970978A1 (en) 2016-01-20
KR20150126048A (ko) 2015-11-10
EP2970978A4 (en) 2016-11-02
AU2014248966A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
Shen et al. Glioma-induced inhibition of caspase-3 in microglia promotes a tumor-supportive phenotype
Bracey et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin‐1β
Gawronska‐Kozak et al. Scarless skin repair in immunodeficient mice
JP2017148075A (ja) 創傷治癒組成物および治療
JP2016135799A (ja) 損傷した創傷治癒組成物および治療
Hu et al. miR-196b-5p-enriched extracellular vesicles from tubular epithelial cells mediated aldosterone-induced renal fibrosis in mice with diabetes
US9878010B2 (en) Methods of treating metabolic disorders
AU2014229985B2 (en) Methods of treating colorectal cancer
US20140303078A1 (en) Modulation of pancreatic beta cell proliferation
Smid et al. Periostin induces pancreatic regeneration
Saidi et al. Glioma-induced SIRT1-dependent activation of hMOF histone H4 lysine 16 acetyltransferase in microglia promotes a tumor supporting phenotype
Pittenger et al. Intramuscular injection of islet neogenesis-associated protein peptide stimulates pancreatic islet neogenesis in healthy dogs
JP2015513905A (ja) カドヘリン調節に基づく組成物および処置
US12006501B2 (en) Composition of drug targets and method of using thereof
JP2010506897A (ja) 脂肪貯蔵と関連した障害を治療する方法
EP3752134B1 (en) Methods and compositions for treating vitiligo
US20170166897A1 (en) Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing
JP6238319B2 (ja) 創傷または線維症の治療剤
US20240139229A1 (en) Treatment for aortopathy
Zou et al. IL-19 promotes psoriasis progression by inhibiting keratinocyte apoptosis via the Bcl-2/Caspase-3 axis
Campbell The Role of Estrogen and Inflammation in Cutaneous Wound Healing
TW201519902A (zh) 絲胺酸蛋白酶抑制蛋白：治療β細胞再生之方法及功能
FULL et al. 21st Annual Meeting of the European Tissue Repair Society
Lubel et al. 478 NEW INSIGHTS INTO THE ANGIOTENSIN 1-7/MAS RECEPTOR INTERACTION FROM A MURINE MODEL OF HEPATIC FIBROSIS AND HEPATIC STELLATE CELL CULTURE

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170308

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20170829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170829